Repligen Corporation
Rank #400Op. LeverageRGEN · Nasdaq · Healthcare
Repligen Corporation (RGEN) — Rank #400 by gross profitability (GP/assets 0.13) · ROE 2.3% · Piotroski F-Score 7 / 9.
As-of 2026-09-28 · CIK 0000730272 · all metrics point-in-time as of the filing date.
About
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Show moreShow less
The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.
The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- repligen.com
Financials
Weakening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross margindeteriorating
- Gross profitabilitydeteriorating
- Net cashn/a
- Operating margindeteriorating
- Return on equitydeteriorating
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-03-14 | 2023-12-31filed 2024-02-22 | 2022-12-31filed 2023-02-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 738.3 | 634.4 | 638.8 | 801.5 |
| Revenue growth (YoY) | 16.4% | 0.3% | -20.3% | 19.5% |
| Gross profit | 386.2 | 274.6 | 284.8 | 455.7 |
| Gross margin | 52.3% | 43.3% | 44.6% | 56.9% |
| Net income | 48.9 | (25.5) | 41.6 | 186.0 |
| Net margin | 6.6% | -4.0% | 6.5% | 23.2% |
| EPS (diluted) | $0.86 | -$0.46 | $0.74 | $3.24 |
| EPS growth (YoY) | 287.0% | -162.2% | -77.2% | — |
| Cash flow | ||||
| Operating cash flow | 117.4 | 175.4 | 113.9 | 172.1 |
| Capital expenditures | 23.5 | 25.7 | 36.2 | 84.8 |
| Free cash flow | 93.9 | 149.7 | 77.7 | 87.2 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?